Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health has appointed Dr. Anula Jayasuriya to its Board of Directors as of July 1, 2022. With extensive experience in healthcare and investment, her expertise is expected to enhance Jaguar's efforts in gastrointestinal medicine development. The company also established a Business Development Advisory Committee, chaired by Rachel Zolot Schwartz, to explore partnerships and acquisitions. These strategic moves aim to strengthen Jaguar's market position and drive growth for its plant-based products, particularly crofelemer.

Jaguar Health (NASDAQ:JAGX) granted 60,000 restricted stock units (RSUs) to New Employee 1 and 12,500 RSUs to New Employee 2 as an inducement for their employment effective June 27, 2022. The RSUs for New Employee 1 will vest fully after one year, while those for New Employee 2 will vest equally over three years. This initiative was approved by the Compensation Committee and is contingent on the employees' continued service with Jaguar. The company focuses on developing sustainable, plant-based medicines for gastrointestinal distress.

Jaguar Health has signed an exclusive license and service agreement with SynWorld Technologies to market Canalevia for treating diarrhea in dogs in China. The agreement includes $5 million in license fees and $5 million in stock purchases over two years. Jaguar is set to receive 60% of profits from sales, increasing to 80% if they cover regulatory costs. The Chinese pet market is projected to reach $70.5 billion by 2023. This agreement aligns with Jaguar's goals for expanding Canalevia's availability and supporting its human pipeline development.

Jaguar Health (NASDAQ:JAGX) announced the online availability of a presentation by Dr. Mohamad Miqdady on Short Bowel Syndrome (SBS) from the Elite Ped-GI Congress in Abu Dhabi, held from May 19-21, 2022. The presentation emphasizes the severe impacts of SBS and congenital diarrheal disorders (CDD), for which current treatment options are limited. The company’s subsidiary, Napo Therapeutics, received orphan-drug designations in the EU and the US for crofelemer, offering hope for patients. The congress aims to update healthcare professionals on pediatric gastroenterology.

Jaguar Health (NASDAQ:JAGX) announced its participation in the ACVIM Forum from June 23-25, 2022, in Austin, TX, to promote Canalevia-CA1, its FDA-conditionally approved treatment for chemotherapy-induced diarrhea in dogs. This product is crucial as many veterinarians report CID impacts chemotherapy plans, highlighting an unmet need. Canalevia-CA1 is derived from the Croton lechleri tree and offers a novel treatment option for affected dogs. The product is available through major veterinary distributors, supporting its commercial launch.

Jaguar Health (NASDAQ:JAGX) announced the publication of an article on June 8, 2022, highlighting the critical need for managing diarrhea in cancer patients, which can affect 50% to 100% of patients undergoing treatment. The article underscores that uncontrolled diarrhea can lead to significant health issues and impact patient quality of life. Jaguar's crofelemer product is in a pivotal Phase 3 trial for preventing diarrhea in adults, while its Canalevia-CA1 for dogs has conditional FDA approval. The company emphasizes the urgency of addressing this side effect for improved treatment outcomes.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all four proposals at its 2022 Annual Meeting of Stockholders held on June 10, 2022. The details of the proposals are available in the definitive proxy statement filed with the SEC. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues, including Mytesi^®, which is specifically for noninfectious diarrhea in HIV/AIDS patients. The company aims to expand access to its products in Europe through its subsidiary Napo Therapeutics.

Jaguar Health (NASDAQ:JAGX) announced its participation in BIO 2022, scheduled for June 13-16, 2022, in San Diego. Karen Brunke, PhD, EVP of Corporate Development, will engage in one-on-one meetings to seek partnerships related to crofelemer, an FDA-approved treatment for diarrhea in adults with HIV/AIDS. The company aims to explore further applications for cancer therapy-related diarrhea and inflammatory bowel disease. Additionally, Jaguar is pursuing collaborations to advance its extensive library of medicinal plants and recently collaborated with Filament Health for developing botanical prescription drugs.

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Therapeutics, has submitted an Orphan Drug Designation application for crofelemer to the European Medicines Agency (EMA) for microvillus inclusion disease (MVID), a severe congenital diarrheal disorder. This submission marks a significant step towards addressing the unmet medical need for MVID, which can cause severe complications in newborns and children. If granted, the designation offers regulatory benefits, including a 10-year market exclusivity upon approval.